Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

UPDATE 1-Australia's Mesoblast posts narrower quarterly loss, rise in R&D costs

Published 25/05/2017, 05:31 pm
Updated 25/05/2017, 05:40 pm
© Reuters.  UPDATE 1-Australia's Mesoblast posts narrower quarterly loss, rise in R&D costs

© Reuters. UPDATE 1-Australia's Mesoblast posts narrower quarterly loss, rise in R&D costs

(Updates throughout with more detail)

May 25 (Reuters) - Australian regenerative medicine maker Mesoblast Ltd MSB.AX on Thursday posted a narrower quarterly loss but booked a rise in research and development costs.

The company reported a net loss of $9.8 million for the three months to March 31, compared with a loss of $16.9 million a year ago.

Total revenue was $901,000, compared with $4.1 million a year ago. Last year's figure was boosted by boosted by deferred commercial revenues for the firm's Mesenchymal Precursor Cell (MPC) technology platform.

With cash reserves of $69.1 million as of March 31, the company reiterated that it needed new funding from a third party partner or via raising further capital to continue in business.

"There is a material uncertainty that may cast significant doubt on the group's ability to continue as a going concern," it said in a filing to the U.S. Securities and Exchange Commission.

However, it said its management and directors believe the company will be successful in meeting funding and debt requirements and the results had been prepared on a going concern basis.

Shares in Mesoblast were down 4.8 percent in late afternoon trade.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.